Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis

Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23137413

DOI
10.1111/jth.12059

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Acute Coronary Syndrome /diagnosis /economics /genetics /mortality /therapy; Aryl Hydrocarbon Hydroxylases /genetics /metabolism; Cerebrovascular Disorders /etiology; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing /economics; Health Care Costs; Hemorrhage /etiology; Humans; Insurance, Health Reimbursement /economics; Kaplan-Meier Estimate; Markov Chains; Medicare /economics; Models, Economic; Myocardial Infarction /etiology; Percutaneous Coronary Intervention /adverse effects /economics /mortality; Pharmacogenetics /economics; Phenotype; Piperazines /economics /metabolism /therapeutic use; Platelet Aggregation Inhibitors /economics /metabolism /therapeutic use; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes /economics /metabolism /therapeutic use; Thrombosis /economics /genetics /prevention & control; Ticlopidine /analogs & derivatives /economics /metabolism /therapeutic use; Time Factors; Treatment Outcome; United States

AccessionNumber
22013008758

Date bibliographic record published
06/03/2013